{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:19Z","timestamp":1792461079592,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35446","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:02:57Z","timestamp":1722312177000},"page":"e35446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023"],"prefix":"10.1016","volume":"10","author":[{"given":"Shan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e35446_bib1","unstructured":"National Psoriasis Foundation. Available from: https:\/\/www.psoriasis.org\/content\/statistics."},{"issue":"10281","key":"10.1016\/j.heliyon.2024.e35446_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e35446_bib4","doi-asserted-by":"crossref","first-page":"adv00769","DOI":"10.2340\/actadv.v102.1386","article-title":"Prevalence and odds of anxiety disorders and anxiety symptoms in children and adults with psoriasis: systematic review and meta-analysis","volume":"102","author":"Jalenques","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.heliyon.2024.e35446_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115078","article-title":"Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019","volume":"321","author":"Liu","year":"2023","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.heliyon.2024.e35446_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2022.111017","article-title":"The prevalence of alexithymia in psoriasis: a systematic review and meta-analysis","volume":"161","author":"Tang","year":"2022","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.heliyon.2024.e35446_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: an update for clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen. Hosp. Psychiatr."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/medicina59020393","article-title":"Knowledge mapping and research hotspots of comorbidities in psoriasis: a bibliometric analysis from 2004 to 2022","volume":"59","author":"Huang","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35446_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e35446_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms222111574","article-title":"Current concepts of psoriasis immunopathogenesis","volume":"22","author":"Vicic","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e35446_bib11","first-page":"11","article-title":"Pathogenesis-oriented therapy of psoriasis using biologics","author":"Boehncke","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.heliyon.2024.e35446_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm. Venereol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35446_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223994","article-title":"Visualizing a field of research: a methodology of systematic scientometric reviews","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tree.2018.11.007","article-title":"Research weaving: visualizing the future of research synthesis","volume":"34","author":"Nakagawa","year":"2019","journal-title":"Trends Ecol. Evol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"Journal of Informetrics"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.joi.2018.03.005","article-title":"Examining the usage, citation, and diffusion patterns of bibliometric mapping software: a comparative study of three tools","volume":"12","author":"Pan","year":"2018","journal-title":"Journal of Informetrics"},{"key":"10.1016\/j.heliyon.2024.e35446_bib18","first-page":"2021","article-title":"TurboBC: a memory efficient and scalable GPU based betweenness centrality algorithm in the language of linear algebra","author":"Artiles","year":"2021","journal-title":"Proc Int Workshops Parallel Proc"},{"key":"10.1016\/j.heliyon.2024.e35446_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102129","article-title":"Neuropsychiatric disturbances in mild cognitive impairment: a scientometric analysis","volume":"92","author":"Amrapala","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"46","key":"10.1016\/j.heliyon.2024.e35446_bib20","doi-asserted-by":"crossref","first-page":"16569","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual's scientific research output","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9625","key":"10.1016\/j.heliyon.2024.e35446_bib22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"52","key":"10.1016\/j.heliyon.2024.e35446_bib23","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35446_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e35446_bib26","first-page":"2102","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study","volume":"29","author":"Di Lernia","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.heliyon.2024.e35446_bib33","first-page":"18","article-title":"Treating psoriasis in the elderly: biologics and small molecules","author":"Megna","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e35446_bib34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14712598.2022.2152322","article-title":"Biologic treatment of psoriasis in oncologic patients","volume":"22","author":"Rusi\u00f1ol","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e35446_bib35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jid.2023.04.009","article-title":"Drug survival of adalimumab, Secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 Years of treatment - a nationwide cohort study","volume":"143","author":"Thein","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35446_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","article-title":"Drug survival of biologic treatments in psoriasis: a systematic review","volume":"29","author":"No","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35446_bib37","first-page":"689","article-title":"A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia","volume":"77","author":"Mashor","year":"2022","journal-title":"Med. J. Malaysia"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","article-title":"Durability and long-term outcomes of biologic therapies in psoriasis","volume":"20","author":"Rusi\u00f1ol","year":"2024","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e35446_bib39","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1097\/CM9.0000000000001232","article-title":"Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis","volume":"133","author":"Wang","year":"2020","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35446_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15052","article-title":"Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland","volume":"34","author":"Owczarek","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35446_bib41","first-page":"1063","article-title":"Biological therapy interruption and Re-treatment in chronic plaque psoriasis","volume":"20","author":"Wang","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdv.12677","article-title":"Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption","volume":"29","author":"Gordon","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35446_bib43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e35446_bib44","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/HAB-210447","article-title":"Immunogenicity of biologics used in the treatment of moderate to severe psoriasis","volume":"29","author":"Patel","year":"2021","journal-title":"Hum. Antibodies"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200870","article-title":"Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States","volume":"34","author":"Armstrong","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35446_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2018-0131","article-title":"Biologics switch in psoriasis","volume":"11","author":"Wang","year":"2019","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1684\/ejd.2011.1330","article-title":"Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis","volume":"21","author":"De Simone","year":"2011","journal-title":"Eur. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1208\/s12248-018-0219-4","article-title":"Investigation of the mechanism of therapeutic protein-drug interaction between methotrexate and golimumab, an anti-TNF\u03b1 monoclonal antibody","volume":"20","author":"Wang","year":"2018","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e35446_bib50","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jdv.19089","article-title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomized controlled trial","volume":"37","author":"van Huizen","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. : JEADV"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.15193","article-title":"Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue","volume":"47","author":"Takamura","year":"2020","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35446_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40257-022-00703-1","article-title":"Combination therapy with apremilast and biologics for psoriasis: a systematic review","volume":"23","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e35446_bib53","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/apt.16883","article-title":"Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease","volume":"55","author":"Townsend","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35446_bib54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5021\/ad.2017.29.6.794","article-title":"Paradoxical flare of psoriasis after ustekinumab therapy","volume":"29","author":"Lee","year":"2017","journal-title":"Ann. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/09546634.2020.1782816","article-title":"Secukinumab retreatment associated psoriasis flare with pustules","volume":"33","author":"El-Komy","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib56","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ced.15006","article-title":"Risankizumab-induced paradoxical pustular psoriasis","volume":"47","author":"McFeely","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.heliyon.2024.e35446_bib57","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. Paradoxical. The Yin-Yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35446_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14225","article-title":"Tumor necrosis factors-\u03b1 inhibition-induced paradoxical psoriasis: a case series and literature review","volume":"33","author":"Lian","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35446_bib59","article-title":"Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment","volume":"15","author":"Chokshi","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib60","first-page":"257","article-title":"Is psoriasis treatment a risk factor for inflammatory bowel disease?","volume":"34","author":"Nehring","year":"2020","journal-title":"Pharmaceut. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e35446_bib61","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib62","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2020.09.087","article-title":"Development of chronic cutaneous lupus erythematosus during biologic therapy: a systematic review","volume":"84","author":"Mirali","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cyto.2014.11.023","article-title":"New pathogenic and therapeutic paradigms in atopic dermatitis","volume":"73","author":"Malajian","year":"2015","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1440-0960.2012.00878.x","article-title":"A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis","volume":"53","author":"Kapila","year":"2012","journal-title":"Australas. J. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35446_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13218","article-title":"Eczematous reaction to ixekizumab successfully treated with dupilumab","volume":"33","author":"Napolitano","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of paradoxical eczema in patients receiving biologics for psoriasis","volume":"160","author":"Al-Janabi","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: a scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35446_bib69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jid.2018.04.041","article-title":"A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis","volume":"139","author":"Foulkes","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35446_bib70","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjd.14888","article-title":"Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort","volume":"176","author":"Zweegers","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35446_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195325","article-title":"Identification of HLA-DRB1 association to adalimumab immunogenicity","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e35446_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15793","article-title":"Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study","volume":"35","author":"Ricceri","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024114776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024114776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:53:58Z","timestamp":1784066038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024114776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":71,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024114776"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35446","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35446"}}